US EditionSun Pharma to buy US drugmaker Organon in $11.75 Billion All-Cash Deal
The deal gives Sun Pharma full ownership of Organon and would create a top-25 global drugmaker with $12.4 billion in combined revenue, the companies said.
- On Sunday, Sun Pharmaceutical Industries Limited announced a definitive agreement to acquire Organon & Co. in an all-cash transaction valued at $11.75 billion, or $14.00 per share.
- Sun Pharma Executive Chairman Dilip Shanghvi said the transaction represents a 'significant opportunity' to build on the company's vision, noting Organon's portfolio and global reach are 'highly complementary' to Sun Pharma's existing business.
- Upon closing, the combined entity expects to rank among the top 25 global pharmaceutical companies with $12.4 billion in revenue, maintaining a presence in 150 countries with 27% revenue share in innovative medicines.
- Following a comprehensive review of strategic alternatives, Organon Executive Chair Carrie Cox stated the board determined the deal offers 'compelling and immediate value' to stockholders, with both boards approving the transaction.
- The transaction is expected to close in early 2027, subject to customary conditions including regulatory approvals and stockholder voting; management cautioned that uncertainties could delay or prevent completion.
43 Articles
43 Articles
Sun Pharmaceutical is paying nearly 12 billion dollars for the originally Dutch company. It concerns one of the largest foreign acquisitions ever by an Indian company.
Sun Pharma to buy US drugmaker Organon for $11.75 billion in India's largest pharma deal
Sun Pharmaceutical Industries will buy U.S. drugmaker Organon & Co in an all-cash deal valued at about $11.75 billion including debt, for the largest overseas acquisition by an Indian pharmaceutical company.
Organon To Be Acquired By Sun Pharma In $11.75B Deal, OGN Stock Spikes Nearly 17% On Robinhood 24-Hour Ma
Organon & Co. has agreed to be acquired by Sun Pharmaceutical Industries in an all-cash deal valued at $11.75 billion, offering shareholders a 103% premium and marking a major step in Sun Pharma's global expansion into women's health and biosimilars.
Sun Pharma to acquire US drugmaker Organon for $11.75 billion: Here are India's biggest outgoing acquisitions
Outbound M&A deals from India reached $22 billion in 2025, led by Tata Motors and others. Sun Pharma is acquiring Organon for $11.75 billion to expand its women's health and biosimilars offerings, buying shares at a premium.
Coverage Details
Bias Distribution
- 57% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
